simply "beyond"
Amplea™ for patients
An acute patient in critical care may suffer from ‘multi-organ failure’ - a crippling and often lethal condition.

AMPLYA™ offers acute patients:
- The most suitable treatment
- Personalized treatment and fast intervention
- Advanced support for organ failure

Amplea™ for critical care staff
AMPLYA™ provides for the needs expressed of nursing and critical care staff, offering:
- The simplicity of one single system to execute the broadest variety of treatment modalities
- The serenity of automated, simple, and round-the-clock management of complex treatments
- A reduction and optimization of operational sequences and time

Amplea™ for clinicians
AMPLYA™ provides for the needs of clinicians, offering:
- Unique therapeutic choice
- Advanced and targeted personalisation capability
- Complete control of the therapeutic process

Therapeutic development
In critical care, tackling organ failures in real-time with an treating diseases such as sepsis, renal failure, respiratory and above 50%. AMPLYA™ is a critical care multitherapeutic from the more conventional to adsorption treatments -
The soul of Amplya™: selective clearance

Blood is the tissue that connects all organs. It controls the functionality of each organ by permitting cellular survival, regulation and growth. It transports nutrients and removes the waste products of cellular metabolism.

Complementary use of filtration and adsorption can remove the molecules involved in organ damage whilst retaining essential components, such as albumin, and can encourage functional recovery of the organ.

AMPLYA™ intervenes in this process by delivering a specific and targeted treatment for an individual disease.

The soul of AMPLYA™ is an innovative concept born from Collaborative Research between University, Hospital and Industry.
Innovative treatments open up new horizons
All kidney replacement modalities
Innovative and specific sorbents
Systemic or locoregional anticoagulation systems
One single set of lines couplable to six blood filters
Low- and high-flux treatments
Direct and continuous hematocrit and oxygen saturation measurement
High treatment autonomy thanks to 3 high-capacity scales

THE RIGHT THERAPY WAY

The added value of Amplya™

COMPLETENESS
- Innovative treatments open up new horizons
- All kidney replacement modalities
- Innovative and specific sorbents
- Systemic or locoregional anticoagulation systems
- One single set of lines couplable to six blood filters
- Low- and high-flux treatments
- Direct and continuous hematocrit and oxygen saturation measurement
- High treatment autonomy thanks to 3 high-capacity scales

AUTOMATION
- Dual cassette plug & play system
- Fast and safe disposable installation
- Fully automated preparation and treatment
- Personalised CPFA™ management with controlled servo-assisted flows
- Automatic level control
- Optical self-recognition of the single use pre-assembled device
- Over 300 hours of stored data, accessible by on PC

INTUITIVENESS
- Touch screen
- Immediate operator interface
- Flexible operating sequences
- One cassette system for all modalities

For patients suffering from:
- ALI (Acute Lung Injury)
- RHEUMATOID ARTHRITIS
- ARDS (Acute Respiratory Distress Syndrome)
- COBP (Chronic Obstructive Bronchopneumopathy)
- CRUSH SYNDROME
- HYPERCHOLESTEROLEMIA
- ARF (Acute Renal Failure)
- MYASTHENIA GRAVIS
- MYELOMA
- MOF: MULTI-ORGAN DYSFUNCTION
- IMMUNE COMPLEX DISEASES
- SEVERE SEPSIS
- SEPTIC SHOCK
Innovative treatments open up new horizons

All kidney replacement modalities

Innovative and specific sorbents

Systemic or locoregional anticoagulation systems

One single set of lines couplable to six blood filters

Low- and high-flux treatments

Direct and continuous hematocrit and oxygen saturation measurement

High treatment autonomy thanks to 3 high-capacity scales

THE RIGHT THERAPY WAY
THE RIGHT THERAPY WAY

AMPLYA™ is capable of performing a broad range of extracorporeal blood clearance therapies with one single circuit. For each specific disease, an unprecedented integrated therapeutic approach aids patient survival and improves quality of life.

The history of Bellco in many ways mirrors the history of extracorporeal blood purification: constant commitment and passion toward Collaborative Research.

Attentiveness, listening to the needs of the medical and scientific communities, along with know-how and innovative capability today make it possible to take another step forward on the road to excellence.

Current and future challenges in critical care require intuitive, versatile systems able to respond to clinical needs in real-time.

AMPLYA™: A LIFE-SAVING SYSTEM

AMPLYA™ is capable of performing a broad range of extracorporeal blood clearance therapies with one single circuit.

For each specific disease, an unprecedented integrated therapeutic approach aids patient survival and improves quality of life.

AMPLYA™: A real and complete multitherapeutic system. A single platform for multiple options.

- CRRT (SCUF, CVVH, CVVHD, CVVHDF)
- IRRT (IHF-HVHF, IHD SLED, IHDF)
- PEX
- CPFA®
- CASCADE FILTRATION
- CO₂ REMOVAL (ABYLCAP & ABYLCAP HD)
Selective clearance: beyond the known patterns

As essential components are retained and waste products eliminated in normal physiological conditions, selective clearance in pathological conditions can only be truly effective if it too can retain essential blood components whilst eliminating toxic ones.

The development of new and more effective clearance technologies to provide optimal therapeutic support for complex diseases.

This is the commitment of the Collaborative Research of universities, clinics and the industry, also testified by the F.A.R.E. Project: Filtration and Adsorption Regione Emilia-Romagna.
Bibliography


